Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmigeneROCO:7595 -2.33%54 Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus rates ROCO:7595 with a GF Score™ of 54/100 and a GF Value™ of NT$24.76 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, Pharmigene ranks worse than 1587300% on this metric.
As of today (2026-07-14), the Forward Annual Dividend Yield of Pharmigene is 0.00%.
As of today (2026-07-14), the Trailing Annual Dividend Yield of Pharmigene is 0.00%.
ROCO:7595's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.03 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
ROCO:7595 vs TMO, DHR, IDXX: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Pharmigene's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmigene Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pharmigene's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Pharmigene's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Pharmigene (ROCO:7595) has a Forward Dividend Yield % of 0.00% as of Jul. 14, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Pharmigene and its competitors. According to the industry distribution chart, Pharmigene ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry.
Is Pharmigene's Forward Dividend Yield % too high?
Pharmigene's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Pharmigene ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pharmigene has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmigene's Forward Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pharmigene ranks #999999 out of 63 companies for Forward Dividend Yield %. This places Pharmigene in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 2.03, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Pharmigene and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmigene's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmigene stock overvalued right now?
Based on GuruFocus' analysis, Pharmigene (ROCO:7595) is currently considered Possible Value Trap. The stock's GF Value™ is NT$24.76, compared to a current price of NT$6.30 — trading 74.6% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Pharmigene's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Pharmigene (ROCO:7595), the current Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmigene (ROCO:7595) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmigene stock appears to be undervalued.
The current stock price of NT$6.30 is trading 74.6% below its estimated GF Value™ of NT$24.76.
GuruFocus considers Pharmigene to be Possible Value Trap.
Key valuation signals for ROCO:7595:
Forward Dividend Yield %: 0.00%
GF Value™: NT$24.76 vs. price of NT$6.30 (74.6% below fair value)
No single metric tells the full story. See the ROCO:7595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.
54GF Score
Get the complete analysis for ROCO:7595
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7595 has been successfully added to your 
